logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

On February 4, 2015, we wrote an article titled, “Aerie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, posted under News & Comments at the Prohost website, we wrote the following: YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE...

Read More

February 18, 2016

0

Exelixis: Great News Towards Great Changes

Exelixis’  ( EXEL )  quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of...

Read More

March 1, 2016

0

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

Agenus (AGEN)   is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines. Missing analysts’ expectation...

Read More

March 3, 2016

0

GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.

London, UK, 14 March 2016:   GW Pharmaceuticals (GWPH) , is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary  cannabinoid product platform . The firm announced the positive results of the first pivotal Phase 3...

Read More

March 14, 2016

0

Vitae Pharmaceuticals: Opening a New Door Towards the Management of Psoriasis. The Drug Could Be Great for Many Other Autoimmune Diseases.

Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. Here we are, a clinical stage small company called  Vitae Pharmaceuticals (VTAE)   has just announced positive results...

Read More

March 17, 2016

0

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine Alder Also Reports Positive Phase 1 Data Supporting Quarterly Single Injection Dosing Strategy for ALD403 Alder BioPharmaceuticals (ALDR)  announced positive...

Read More

March 28, 2016

0

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg for the treatment of metastatic neuro-endocrine syndrome (mNET) patients who suffer from carcinoid syndrome diarrhea. The drug will be launched and sold today, March...

Read More

March 6, 2017

0

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of a combination of Exelixis cabozantinib in combination with Roche’s anti-PD-L1 immuno-therapy drug atezolizumab. The study aims at evaluating the safety and tolerability  of the...

Read More

February 27, 2017

0

Agenus: Why Canceling Prophage Trial Should Not be Concerning

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk...

Read More

February 22, 2017

0

OncoCyte's Liquid Biopsy Test Has Positive News

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests has good news about its lung cancer liquid biopsy. Liquid biopsy is a term recently coined for a simple blood test that can replace...

Read More

March 15, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 15
  • 16
  • 17
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy